“`html
Alnylam’s Zilebesiran Blood pressure Trial Shows Inconclusive Results
An investigational therapy from Alnylam Pharmaceuticals did not considerably lower blood pressure in a key Phase 2 trial, raising questions about the benefit of the twice-a-year treatment as it enters late-stage testing.
Among high-risk patients already taking at least two common hypertension treatments, a 300-mg dose of Alnylam’s zilebesiran led to a reduction in blood pressure of 5 millimeters of mercury (mmHG) lower then placebo at three months. By six months, the difference was 3.9 mmHG. However, thes results were not considered statistically importent, according to data released Saturday at a meeting of the European Society of Cardiology.
Researchers also tested a higher dose 600 mg of zilebesiran, but didn’t observe additional benefits.
Zilebesiran’s impact on Hypertension Treatment
“These results were not considered statistically significant, according to data released Saturday at a meeting of the European Society of Cardiology.”
The findings have prompted discussions about the future direction of hypertension therapies and the potential role of zilebesiran.
